TMUB2

Across TCGA pan-cancer cohorts, TMUB2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TMUB2 data layer compared with 28 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TMUB2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMUB2 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

CCRCC, HNSC, and LUAD are the cancer types where TMUB2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.834	0.972	.008	23	view →
HNSC	DFS	Tertile	All	0.402	0.947	.011	12	view →
LUAD	DFS	Median	III,IV	0.716	0.300	.013	7	view →
PDAC	OS	Median	All	0.781	0.915	.007	5	view →
LSCC	OS	Median	All	0.793	1.000	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TMUB2–CCRCC (DFS)

Open the CCRCC breakdown →